Stereotactic magnetic resonance guided adaptive radiation therapy (SMART) is a new option for local treatment of unresectable pancreatic ductal adenocarcinoma, showing interesting survival and local control (LC) results. Despite this, some patients will experience early local and/or metastatic recurrence leading to death. We aimed to develop multiparametric prognostic models for these patients. All patients treated in our institution with SMART for an unresectable pancreatic ductal adenocarcinoma between October 21, 2019, and August 5, 2022 were included. Several initial clinical characteristics as well as dosimetric data of SMART were recorded. Radiomics data from 0.35-T simulation magnetic resonance imaging were extracted. All these data were combined to build prognostic models of overall survival (OS) and LC using machine learning algorithms. Eighty-three patients with a median age of 64.9 years were included. A majority of patients had a locally advanced pancreatic cancer (77%). The median OS was 21 months after SMART completion and 27 months after chemotherapy initiation. The 6- and 12-month post-SMART OS was 87.8% (IC95%, 78.2%-93.2%) and 70.9% (IC95%, 58.8%-80.0%), respectively. The best model for OS was the Cox proportional hazard survival analysis using clinical data, with a concordance index inverse probability of censoring weighted of 0.87. Tested on its 12-month OS prediction capacity, this model had good performance (sensitivity 67%, specificity 71%, and area under the curve 0.90). The median LC was not reached. The 6- and 12-month post-SMART LC was 92.4% [IC95%, 83.7%-96.6%] and 76.3% [IC95%, 62.6%-85.5%], respectively. The best model for LC was the component-wise gradient boosting survival analysis using clinical and radiomics data, with a concordance index inverse probability of censoring weighted of 0.80. Tested on its 9-month LC prediction capacity, this model had good performance (sensitivity 50%, specificity 97%, and area under the curve 0.78). Combining clinical and radiomics data in multiparametric prognostic models using machine learning algorithms showed good performance for the prediction of OS and LC. External validation of these models will be needed.

Chronic liver disease (CLD) is a substantial cause of morbidity and mortality worldwide. Liver stiffness, as measured by MR elastography (MRE), is well-accepted as a surrogate marker of liver fibrosis. To develop and validate deep learning (DL) models for predicting MRE-derived liver stiffness using routine clinical non-contrast abdominal T1-weighted (T1w) and T2-weighted (T2w) data from multiple institutions/system manufacturers in pediatric and adult patients. We identified pediatric and adult patients with known or suspected CLD from four institutions, who underwent clinical MRI with MRE from 2011 to 2022. We used T1w and T2w data to train DL models for liver stiffness classification. Patients were categorized into two groups for binary classification using liver stiffness thresholds (≥ 2.5 kPa, ≥ 3.0 kPa, ≥ 3.5 kPa, ≥ 4 kPa, or ≥ 5 kPa), reflecting various degrees of liver stiffening. We identified 4695 MRI examinations from 4295 patients (mean ± SD age, 47.6 ± 18.7 years; 428 (10.0%) pediatric; 2159 males [50.2%]). With a primary liver stiffness threshold of 3.0 kPa, our model correctly classified patients into no/minimal (< 3.0 kPa) vs moderate/severe (≥ 3.0 kPa) liver stiffness with AUROCs of 0.83 (95% CI: 0.82, 0.84) in our internal multi-site cross-validation (CV) experiment, 0.82 (95% CI: 0.80, 0.84) in our temporal hold-out validation experiment, and 0.79 (95% CI: 0.75, 0.81) in our external leave-one-site-out CV experiment. The developed model is publicly available ( https://github.com/almahdir1/Multi-channel-DeepLiverNet2.0.git ). Our DL models exhibited reasonable diagnostic performance for categorical classification of liver stiffness on a large diverse dataset using T1w and T2w MRI data. Question Can DL models accurately predict liver stiffness using routine clinical biparametric MRI in pediatric and adult patients with CLD? Findings DeepLiverNet2.0 used biparametric MRI data to classify liver stiffness, achieving AUROCs of 0.83, 0.82, and 0.79 for multi-site CV, hold-out validation, and external CV. Clinical relevance Our DeepLiverNet2.0 AI model can categorically classify the severity of liver stiffening using anatomic biparametric MR images in children and young adults. Model refinements and incorporation of clinical features may decrease the need for MRE.

Accurate preoperative evaluation of myometrial invasion (MI) is essential for treatment decisions in endometrial cancer (EC). However, the diagnostic accuracy of commonly utilized magnetic resonance imaging (MRI) techniques for this assessment exhibits considerable variability. This study aims to enhance preoperative discrimination of absence or presence of MI by developing and validating a multimodal deep learning radiomics (MDLR) model based on MRI. During March 2010 and February 2023, 1139 EC patients (age 54.771 ± 8.465 years; range 24-89 years) from five independent centers were enrolled retrospectively. We utilized ResNet18 to extract multi-scale deep learning features from T2-weighted imaging followed by feature selection via Mann-Whitney U test. Subsequently, a Deep Learning Signature (DLS) was formulated using Integrated Sparse Bayesian Extreme Learning Machine. Furthermore, we developed Clinical Model (CM) based on clinical characteristics and MDLR model by integrating clinical characteristics with DLS. The area under the curve (AUC) was used for evaluating diagnostic performance of the models. Decision curve analysis (DCA) and integrated discrimination index (IDI) were used to assess the clinical benefit and compare the predictive performance of models. The MDLR model comprised of age, histopathologic grade, subjective MR findings (TMD and Reading for MI status) and DLS demonstrated the best predictive performance. The AUC values for MDLR in training set, internal validation set, external validation set 1, and external validation set 2 were 0.899 (95% CI, 0.866-0.926), 0.874 (95% CI, 0.829-0.912), 0.862 (95% CI, 0.817-0.899) and 0.867 (95% CI, 0.806-0.914) respectively. The IDI and DCA showed higher diagnostic performance and clinical net benefits for the MDLR than for CM or DLS, which revealed MDLR may enhance decision-making support. The MDLR which incorporated clinical characteristics and DLS could improve preoperative accuracy in discriminating absence or presence of MI. This improvement may facilitate individualized treatment decision-making for EC.

This review provides a critical analysis of recent advancements in active surveillance (AS), emphasizing updates from major international guidelines and their implications for clinical practice. Recent revisions to international guidelines have broadened the eligibility criteria for AS to include selected patients with ISUP grade group 2 prostate cancer. This adjustment acknowledges that certain intermediate-risk cancers may be appropriate for AS, reflecting a heightened focus on achieving a balance between oncologic control and maintaining quality of life by minimizing the risk of overtreatment. This review explores key innovations in AS for prostate cancer, including multi parametric magnetic resonance imaging (mpMRI), genomic biomarkers, and risk calculators, which enhance patient selection and monitoring. While promising, their routine use remains debated due to guideline inconsistencies, cost, and accessibility. Special focus is given to biomarkers for identifying ISUP grade group 2 cancers suitable for AS. Additionally, the potential of artificial intelligence to improve diagnostic accuracy and risk stratification is examined. By integrating these advancements, this review provides a critical perspective on optimizing AS for more personalized and effective prostate cancer management.

In pancreatic stereotactic body radiotherapy (SBRT), accurate motion management is crucial for the safe delivery of high doses per fraction. Intra-fraction tracking with magnetic resonance imaging-guidance for gated SBRT has shown potential for improved local control. Visualisation of pancreas (and surrounding organs) remains challenging in intra-fraction kilo-voltage (kV) imaging, requiring implanted fiducials. In this study, we investigate patient-specific deep-learning approaches to track the gross-tumour-volume (GTV), pancreas-head and the whole-pancreas in intra-fraction kV images. Conditional-generative-adversarial-networks were trained and tested on data from 25 patients enrolled in an ethics-approved pancreatic SBRT trial for contour prediction on intra-fraction 2D kV images. Labelled digitally-reconstructed-radiographs (DRRs) were generated from contoured planning-computed-tomography (CTs) (CT-DRRs) and cone-beam-CTs (CBCT-DRRs). A population model was trained using CT-DRRs of 19 patients. Two patient-specific model types were created for six additional patients by fine-tuning the population model using CBCT-DRRs (CBCT-models) or CT-DRRs (CT-models) acquired in exhale-breath-hold. Model predictions on unseen triggered-kV images from the corresponding six patients were evaluated against projected-contours using Dice-Similarity-Coefficient (DSC), centroid-error (CE), average Hausdorff-distance (AHD), and Hausdorff-distance at 95th-percentile (HD95). The mean ± 1SD (standard-deviation) DSCs were 0.86 ± 0.09 (CBCT-models) and 0.78 ± 0.12 (CT-models). For AHD and CE, the CBCT-model predicted contours within 2.0 mm ≥90.3 % of the time, while HD95 was within 5.0 mm ≥90.0 % of the time, and had a prediction time of 29.2 ± 3.7 ms per contour. The patient-specific CBCT-models outperformed the CT-models and predicted the three contours with 90th-percentile error ≤2.0 mm, indicating the potential for clinical real-time application.

This study aimed to evaluate the application of a contrast-enhanced CT-based visual model in predicting postoperative prognosis in patients with hepatoblastoma (HB). We analyzed data from 224 patients across three centers (178 in the training cohort, 46 in the validation cohort). Visual features were extracted from contrast-enhanced CT images, and key features, along with clinicopathological data, were identified using LASSO Cox regression. Visual (DINOv2_score) and clinical (Clinical_score) models were developed, and a combined model integrating DINOv2_score and clinical risk factors was constructed. Nomograms were created for personalized risk assessment, with calibration curves and decision curve analysis (DCA) used to evaluate model performance. The DINOv2_score was recognized as a key prognostic indicator for HB. In both the training and validation cohorts, the combined model demonstrated superior performance in predicting disease-free survival (DFS) [C-index (95% CI): 0.886 (0.879-0.895) and 0.873 (0.837-0.909), respectively] and overall survival (OS) [C-index (95% CI): 0.887 (0.877-0.897) and 0.882 (0.858-0.906), respectively]. Calibration curves showed strong alignment between predicted and observed outcomes, while DCA demonstrated that the combined model provided greater clinical net benefit than the clinical or visual models alone across a range of threshold probabilities. The contrast-enhanced CT-based visual model serves as an effective tool for predicting postoperative prognosis in HB patients. The combined model, integrating the DINOv2_score and clinical risk factors, demonstrated superior performance in survival prediction, offering more precise guidance for personalized treatment strategies.

Steatotic liver disease (SLD) is the most common liver disease worldwide, affecting 30% of the global population. It is strongly associated with the interplay of genetic and lifestyle-related risk factors. The genetic variant accounting for the largest fraction of SLD heritability is PNPLA3 I148M, which is carried by 23% of the western population and increases the risk of SLD two to three-fold. However, identification of variant carriers is not part of routine clinical care and prevents patients from receiving personalised care. We analysed MRI images and common genetic variants in PNPLA3, TM6SF2, MTARC1, HSD17B13 and GCKR from a cohort of 45 603 individuals from the UK Biobank. Proton density fat fraction (PDFF) maps were generated using a water-fat separation toolbox, applied to the magnitude and phase MRI data. The liver region was segmented using a U-Net model trained on 600 manually segmented ground truth images. The resulting liver masks and PDFF maps were subsequently used to calculate liver PDFF values. Individuals with (PDFF ≥ 5%) and without SLD (PDFF < 5%) were selected as the study cohort and used to train and test a Vision Transformer classification model with five-fold cross validation. We aimed to differentiate individuals who are homozygous for the PNPLA3 I148M variant from non-carriers, as evaluated by the area under the receiver operating characteristic curve (AUROC). To ensure a clear genetic contrast, all heterozygous individuals were excluded. To interpret our model, we generated attention maps that highlight the regions that are most predictive of the outcomes. Homozygosity for the PNPLA3 I148M variant demonstrated the best predictive performance among five variants with AUROC of 0.68 (95% CI: 0.64-0.73) in SLD patients and 0.57 (95% CI: 0.52-0.61) in non-SLD patients. The AUROCs for the other SNPs ranged from 0.54 to 0.57 in SLD patients and from 0.52 to 0.54 in non-SLD patients. The predictive performance was generally higher in SLD patients compared to non-SLD patients. Attention maps for PNPLA3 I148M carriers showed that fat deposition in regions adjacent to the hepatic vessels, near the liver hilum, plays an important role in predicting the presence of the I148M variant. Our study marks novel progress in the non-invasive detection of homozygosity for PNPLA3 I148M through the application of deep learning models on MRI images. Our findings suggest that PNPLA3 I148M might affect the liver fat distribution and could be used to predict the presence of PNPLA3 variants in patients with fatty liver. The findings of this research have the potential to be integrated into standard clinical practice, particularly when combined with clinical and biochemical data from other modalities to increase accuracy, enabling easier identification of at-risk individuals and facilitating the development of tailored interventions for PNPLA3 I148M-associated liver disease.

To evaluate the diagnostic performance of a machine learning model combining deep learning models based on enhanced CT images with radiological and clinical features in differentiating lipid-poor adrenal adenomas from metastatic tumors, and to explain the model's prediction results through SHAP(Shapley Additive Explanations) analysis. A retrospective analysis was conducted on abdominal contrast-enhanced CT images and clinical data from 416 pathologically confirmed adrenal tumor patients at our hospital from July 2019 to December 2024. Patients were randomly divided into training and testing sets in a 7:3 ratio. Six convolutional neural network (CNN)-based deep learning models were employed, and the model with the highest diagnostic performance was selected based on the area under curve(AUC) of the ROC. Subsequently, multiple machine learning models incorporating clinical and radiological features were developed and evaluated using various indicators and AUC.The best-performing machine learning model was further analyzed using SHAP plots to enhance interpretability and quantify feature contributions. All six deep learning models demonstrated excellent diagnostic performance, with AUC values exceeding 0.8, among which ResNet50 achieved the highest AUC. Among the 10 machine learning models incorporating clinical and imaging features, the extreme gradient boosting(XGBoost) model exhibited the best accuracy(ACC), sensitivity, and AUC, indicating superior diagnostic performance.SHAP analysis revealed contributions from ResNet50, RPW, age, and other key features in model predictions. Machine learning models based on contrast-enhanced CT combined with clinical and imaging features exhibit outstanding diagnostic performance in differentiating lipid-poor adrenal adenomas from metastases.

The aim of this study was to intraindividually compare the conspicuity of focal liver lesions (FLLs) between low- and ultra-low-dose computed tomography (CT) with deep learning reconstruction (DLR) and standard-dose CT with model-based iterative reconstruction (MBIR) from a single CT using dual-split scan in patients with suspected liver metastasis via a noninferiority design. This prospective study enrolled participants who met the eligibility criteria at 2 tertiary hospitals in South Korea from June 2022 to January 2023. The criteria included ( a ) being aged between 20 and 85 years and ( b ) having suspected or known liver metastases. Dual-source CT scans were conducted, with the standard radiation dose divided in a 2:1 ratio between tubes A and B (67% and 33%, respectively). The voltage settings of 100/120 kVp were selected based on the participant's body mass index (<30 vs ≥30 kg/m 2 ). For image reconstruction, MBIR was utilized for standard-dose (100%) images, whereas DLR was employed for both low-dose (67%) and ultra-low-dose (33%) images. Three radiologists independently evaluated FLL conspicuity, the probability of metastasis, and subjective image quality using a 5-point Likert scale, in addition to quantitative signal-to-noise and contrast-to-noise ratios. The noninferiority margins were set at -0.5 for conspicuity and -0.1 for detection. One hundred thirty-three participants (male = 58, mean body mass index = 23.0 ± 3.4 kg/m 2 ) were included in the analysis. The low- and ultra-low- dose had a lower radiation dose than the standard-dose (median CT dose index volume: 3.75, 1.87 vs 5.62 mGy, respectively, in the arterial phase; 3.89, 1.95 vs 5.84 in the portal venous phase, P < 0.001 for all). Median FLL conspicuity was lower in the low- and ultra-low-dose scans compared with the standard-dose (3.0 [interquartile range, IQR: 2.0, 4.0], 3.0 [IQR: 1.0, 4.0] vs 3.0 [IQR: 2.0, 4.0] in the arterial phase; 4.0 [IQR: 1.0, 5.0], 3.0 [IQR: 1.0, 4.0] vs 4.0 [IQR: 2.0, 5.0] in the portal venous phases), yet within the noninferiority margin ( P < 0.001 for all). FLL detection was also lower but remained within the margin (lesion detection rate: 0.772 [95% confidence interval, CI: 0.727, 0.812], 0.754 [0.708, 0.795], respectively) compared with the standard-dose (0.810 [95% CI: 0.770, 0.844]). Sensitivity for liver metastasis differed between the standard- (80.6% [95% CI: 76.0, 84.5]), low-, and ultra-low-doses (75.7% [95% CI: 70.2, 80.5], 73.7 [95% CI: 68.3, 78.5], respectively, P < 0.001 for both), whereas specificity was similar ( P > 0.05). Low- and ultra-low-dose CT with DLR showed noninferior FLL conspicuity and detection compared with standard-dose CT with MBIR. Caution is needed due to a potential decrease in sensitivity for metastasis ( clinicaltrials.gov/NCT05324046 ).

Automatic clinical tumor volume (CTV) delineation is pivotal to improving outcomes for interstitial brachytherapy cervical cancer. However, the prominent differences in gray values due to the interstitial needles bring great challenges on deep learning-based segmentation model. In this study, we proposed a novel interstitial-guided segmentation network termed advance reverse guided network (ARGNet) for cervical tumor segmentation with interstitial brachytherapy. Firstly, the location information of interstitial needles was integrated into the deep learning framework via multi-task by a cross-stitch way to share encoder feature learning. Secondly, a spatial reverse attention mechanism is introduced to mitigate the distraction characteristic of needles on tumor segmentation. Furthermore, an uncertainty area module is embedded between the skip connections and the encoder of the tumor segmentation task, which is to enhance the model's capability in discerning ambiguous boundaries between the tumor and the surrounding tissue. Comprehensive experiments were conducted retrospectively on 191 CT scans under multi-course interstitial brachytherapy. The experiment results demonstrated that the characteristics of interstitial needles play a role in enhancing the segmentation, achieving the state-of-the-art performance, which is anticipated to be beneficial in radiotherapy planning.